Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

In late 2021, Pfizer (PFE-0.21%) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine. It followed that success with the launch ...

Pfizer stock has fallen over 60% since its peak at $61.71 during the pandemic, driven by its COVID-19 vaccine sales. Pfizer’s revenue finally rose 2.1% YoY in its second quarter of 2024, for the ...

Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.

Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...

Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

High Yielding Pfizer Looks Bullish (Technical Analysis) Jul. 28, 2024 2:52 AM ET Pfizer Inc. (PFE) Stock , PFE:CA Stock PFE , PFE:CA 25 Comments 7 Likes Walter Zelezniak Jr ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer now anticipates revenue in the range of $61 billion to $64 billion and earnings per share to arrive between $2.75 to $2.95. This is higher than its previous forecast for revenue of $59.5 ...

The stock price of Pfizer (NYSE: PFE) has outperformed the broader indices. While the S&P500 index has seen a rise of 1% over the last month or so, PFE stock is up a solid 19%. This also compares ...